Pipelines

We have established a portfolio of promising pipelines targeting immune cells to combat neurodegenerative diseases. Our selection criteria include technical novelty, unmet medical need, safety, and accelerated path to clinical trials.


NiT-1

NiT-1 develops pharmacological agents that transform residential immune cells in the central nervous system. Transformed cells clear out the alpha-synuclein aggregates and stop the progress of neurodegeneration.

Read more

NiT-2

NiT-2 utilizes innovative technology to engineer immune cells from the bloodstream, enhancing the immune response in the nervous system. This groundbreaking approach aims to prevent the development of neurological disorders, including synucleinopathy, by bolstering the body’s natural defenses.

Read more